World’s First Live Birth Using REPROCELL’s StemRNA Clinical Seed iPSCs for Oocyte Maturation Outside of the Body

Corporate NewsLeave a comment

REPROCELL is thrilled to celebrate a groundbreaking milestone by our partner Gameto, who recently announced the birth of the first baby born using Fertilo, a proprietary in vitro oocyte maturation technology. This major medical advancement marks a pivotal breakthrough in redefining women’s healthcare, supported by our StemRNA™ Clinical induced Pluripotent Stem Cells (iPSCs).

Qkine announces partnership with REPROCELL

Corporate NewsLeave a comment

Qkine announces partnership with REPROCELL: Global distributorship for high quality bioactive proteins for stem cell culture Cambridge, UK and Yokohama, Japan – Qkine Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, and REPROCELL Inc., Japan’s first and leading induced pluripotent stem cell (iPSC) company, have partnered to globally…